Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/05/2013US8574558 UV-curable nail coating formulations based on renewable polyols
11/05/2013US8574557 Composition for a cosmetic and a cosmetic comprising the same
11/05/2013US8574552 Solid dosage formulations of narcotic drugs having improved buccal adsorption
11/05/2013US8574420 Ultrathin multilayered films for controlled release of anionic reagents
11/05/2013CA2762911C Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
11/05/2013CA2752865C Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent
11/05/2013CA2731403C Pyrrolidin-3-ylmethyl-amine as orexin antagonists
11/05/2013CA2722734C 3,4-substituted piperidine derivatives as renin inhibitors
11/05/2013CA2678165C Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
11/05/2013CA2672722C Methods of preparing substituted tetracyclines with transition metal-based chemistries
11/05/2013CA2656064C Polymorphic forms and process
11/05/2013CA2610194C Stable active compound complex of salts of o-acetylsalicylic acid with basic amino acids and glycine
11/05/2013CA2605112C Solid transdermal therapeutic system comprising uv absorber
11/05/2013CA2603594C Micronized tanaproget and compositions containing same
11/05/2013CA2600169C Pyrazine -2-carboxamide derivatives as mglur5 antagonists
11/05/2013CA2594345C Compositions and methods of treating cell proliferation disorders
11/05/2013CA2593578C Cxcr4 antagonists for the treatment of medical disorders
11/05/2013CA2590157C Solid forms of a chemokine receptor antagonist and methods of use thereof
11/05/2013CA2576049C Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning
11/05/2013CA2550718C Cohesive gels from cross-linked hyaluronan and/or hylan, their preparation and use
11/05/2013CA2492803C Oxime conjugates and methods for their formation and use
11/05/2013CA2491994C Modulators of the glucocorticoid receptor
11/05/2013CA2467936C Method of inhibiting gene expression
11/05/2013CA2461305C Methods of suppressing microglial activation and systemic inflammatory responses
11/05/2013CA2394015C Tweak receptor
10/2013
10/31/2013WO2013163576A1 Pantothenate derivatives for the treatment of neurologic disorders
10/31/2013WO2013163562A2 Compositions and methods for treating ptsd and related diseases
10/31/2013WO2013163545A1 Use of n-acetylcysteine amide in the treatment of disease and injury
10/31/2013WO2013163512A1 Agents and methods for treating and preventing seborrheic keratosis
10/31/2013WO2013163508A1 Tetrahydropyran dgat1 inhibitors
10/31/2013WO2013163466A1 Inhibitors of hepatitis c virus
10/31/2013WO2013163455A2 A drug screening platform for rett syndrome
10/31/2013WO2013163404A1 TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
10/31/2013WO2013163402A1 Methods for treatment of 16p11.2 microdeletion syndrome
10/31/2013WO2013163344A1 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
10/31/2013WO2013163279A1 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
10/31/2013WO2013163270A1 Hepatitis c virus inhibitors
10/31/2013WO2013163258A1 Microrna compounds and methods for modulating mir-21 activity
10/31/2013WO2013163244A1 Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
10/31/2013WO2013163241A1 Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
10/31/2013WO2013163239A1 Synthesis of lactams
10/31/2013WO2013163219A1 Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
10/31/2013WO2013163214A1 Formulations and methods for delaying onset of chronic neuropathic pain
10/31/2013WO2013163159A2 Design and synthesis of novel inhibitors of isoprenoid biosynthesis
10/31/2013WO2013163142A1 Liquid pharmaceutical formulation containing ketorolac and tramadol
10/31/2013WO2013162922A1 Taxane compounds, compositions and methods
10/31/2013WO2013162828A1 Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
10/31/2013WO2013162757A1 Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use
10/31/2013WO2013162727A1 Methods and compositions for raf kinase mediated diseases
10/31/2013WO2013162714A1 Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
10/31/2013WO2013162469A1 Tubulin inhibitors
10/31/2013WO2013162416A1 Broncholytic drug on the basis of prostaglandin
10/31/2013WO2013162413A1 Pharmaceutical composition of an s1p receptor agonist for treating demyelinated disorders (alternatives) and method for producing same
10/31/2013WO2013162382A1 Method for detoxification or measurement of at least one compound or at least one fluid in a host body
10/31/2013WO2013162363A1 RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
10/31/2013WO2013162298A1 Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
10/31/2013WO2013162061A1 Bicyclic pyrimidine compound
10/31/2013WO2013162054A1 Composition for controlling chromatin structure
10/31/2013WO2013162048A1 Injectable preparation
10/31/2013WO2013162047A1 Therapeutic agent for secondary hyperparathyroidism
10/31/2013WO2013162046A1 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
10/31/2013WO2013162041A1 Unit structure-type pharmaceutical composition for nucleic acid delivery
10/31/2013WO2013162027A1 Neuronal differentiation promoter
10/31/2013WO2013162021A1 Prophylactic or therapeutic agent for hepatic diseases
10/31/2013WO2013162016A1 New carbamate glycolipid and use thereof
10/31/2013WO2013161994A1 Analgesic
10/31/2013WO2013161993A1 Trans-2-decenoic acid derivative and drug containing same
10/31/2013WO2013161980A1 Cyclohexanediamide derivative and use thereof for medical purposes
10/31/2013WO2013161978A1 Hair growth agent
10/31/2013WO2013161973A1 Method for treating irritable bowel syndrome with diarrhea
10/31/2013WO2013161933A1 Deuterated nitrogen-containing heterocyclic carboxamide derivative
10/31/2013WO2013161929A1 Pyridinyl morpholinone derivative and drug composition containing same
10/31/2013WO2013161928A1 Oxazolotriazole derivative and drug composition containing same
10/31/2013WO2013161919A1 Trk-INHIBITING COMPOUND
10/31/2013WO2013161913A1 Nitrogenated heterocyclic compound
10/31/2013WO2013161904A1 Sulfonamide derivative and medicinal use thereof
10/31/2013WO2013161871A1 Thiophene derivative having tlr-inhibiting activity
10/31/2013WO2013161853A1 Quinazolinedione derivative
10/31/2013WO2013161851A1 Benzamide derivative
10/31/2013WO2013161848A1 Novel 1,2,4-triazine derivative
10/31/2013WO2013161842A1 Method for producing zaltoprofen and derivative thereof
10/31/2013WO2013161830A1 Injectable formulation
10/31/2013WO2013161823A1 Orally disintegrating tablet and method for producing same
10/31/2013WO2013161821A1 Cgrp responsiveness promoter
10/31/2013WO2013161820A1 Composition for promoting bifidobacteria growth
10/31/2013WO2013161816A1 Amine compound and use thereof for medical purposes
10/31/2013WO2013161815A1 Tablet containing glutamic acid and arginine at high contents
10/31/2013WO2013161471A1 Medicament for treating mental and behavioural disorders
10/31/2013WO2013161378A1 Method for producing composition containing fucoxanthin
10/31/2013WO2013161359A1 Enteral environment-improving agent
10/31/2013WO2013161312A1 Pyrrolopyridinone derivatives as ttx-s blockers
10/31/2013WO2013161308A1 Amide derivatives as ttx-s blockers
10/31/2013WO2013160916A1 Sunitinib malate solid dispersion
10/31/2013WO2013160914A1 Novel synergistic composition comprising of a carotenoid, serm and an amino acid derivative thereof
10/31/2013WO2013160909A1 Stable composition of fesoterodine
10/31/2013WO2013160896A1 Pomegranate oil for preventing and treating neurodegenerative diseases
10/31/2013WO2013160895A1 Peptides and use thereof in the treatment of large cell lung cancer
10/31/2013WO2013160875A1 Process for manufacturing naphthyridine derivatives
10/31/2013WO2013160873A1 Cyclic bridgehead ether dgat1 inhibitors
10/31/2013WO2013160792A1 Compositions comprising ornithine alpha-ketoglutarate, processes for their preparation and their use.
1 ... 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 ... 7860